SteadyMed Outlines Strategic Goals and Priorities for 2017

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans

SAN RAMON, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced updates to its key strategic goals and its priorities for 2017.

They include:

  • Filing of a New Drug Application (NDA) for Trevyent ® for the treatment of Pulmonary Arterial Hypertension (PAH) in Q2.
  • Obtaining a favorable ruling in our Inter Partes Review (IPR) challenge against U.S. Patent No. 8,497,393 (the '393 patent) owned by United Therapeutics Corporation in early Q2.
  • Subject to the granting of Priority Review of the NDA for Trevyent, obtaining approval for commercial sale of Trevyent by the U.S. Food and Drug Administration (FDA) in Q4.
  • Subject to approval of Trevyent, obtaining Orphan Exclusivity from the FDA and securing seven (7) years of market exclusivity.
  • Continuing to create awareness of PAH via our BePhenomenal pulmonary hypertension community support program. Please visit www.BePhenomenal.com for more information.

“2017 is expected to be a pivotal year for SteadyMed as we focus our resources on key strategic goals and priorities related to the approval of our lead drug product candidate Trevyent,” said Jonathan Rigby, President & CEO of SteadyMed. “We are confident that we can execute on these initiatives and priorities. With our existing cash, plus the $10.7 million that is callable upon achievement of certain milestones per the second tranche of our last private financing, we can fund operations for at least the next twelve months. We are now eagerly looking forward to the commercial launch of Trevyent, if approved, in 2018.”

About SteadyMed SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit  www.steadymed.com .

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements about the company's ability to advance its development-stage product candidates, including Trevyent. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA, that Trevyent is not granted orphan drug exclusivity, the risk that drug development involves a lengthy and expensive process with uncertain outcome, that the company does not receive a favorable ruling in its IPR challenge, that the company will not satisfy the milestone and other closing conditions to call the second tranche of its July 2016 private placement, that the company will continue to need additional funding, and that the company may be unable to raise capital when needed, which would force the company to delay, reduce or eliminate its product candidate development programs and potentially cease operations. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed on November 14, 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

Contact: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 8

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 101

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 10

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 99

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 159

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 229

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into National HealthCare Corporation by Kaskela Law

Updated Category News Views 203

Kaskela Law LLC Announces Investigation Kaskela Law LLC has recently launched an investigation into National HealthCare Corporation (NYSE: NHC) on behalf of its shareholders. This inquiry seeks to determine if the company or its executives have violated securities laws or breached their fiduciary duties in light of recent corporate actions. Investigation Objectives The...

Continue Reading
HOPE Therapeutics Expands Its Reach in Florida’s Mental Health Care

Updated Category News Views 161

HOPE Therapeutics Welcomes Cohen & Associates to the Network In an exciting advancement, HOPE Therapeutics, Inc. has recently integrated Cohen & Associates, LLC into its expanding professional framework, aimed at revolutionizing the landscape of interventional psychiatry. This noteworthy inclusion signals a meaningful step in enhancing mental health services across...

Continue Reading
Abdullah Abdin Ready Mix Concrete's Historic Certification Milestone

Updated Category News Views 217

Abdullah Abdin Ready Mix Concrete Announces Historic Achievement Setting new standards in sustainability and innovation, Abdullah Abdin Ready-Mix Concrete has proudly achieved the prestigious Concrete Sustainability Council (CSC) certification. This recognition establishes the company as the first ready-mix concrete firm in the MENA region to receive such an influential...

Continue Reading
The Tragic Shooting of Charlie Kirk: National Outrage Ensues

Updated Category News Views 393

The Shocking Assassination of Charlie Kirk Conservative political activist Charlie Kirk was tragically shot and killed while addressing a gathering. This shocking incident has ignited a series of investigations and public responses, leading to numerous political reactions across the nation. Details Surrounding the Incident The violent act took place during Kirk's speech,...

Continue Reading
Cibus Global Ltd. Faces Market Challenges with Stock Dip

Updated Category News Views 129

Cibus Global Ltd. Faces Significant Stock Decline In recent trading sessions, Cibus Global Ltd. (CBUS) stock encountered a dramatic decline, hitting a 52-week low of $2.36. This notable drop is stark when compared to its previous high of $23.18, showing a staggering reduction of approximately 88.48% over the past year. The plummeting share price has raised alarms among...

Continue Reading